Opthea (ASX:OPT) aims to revolutionize wet AMD treatment

Opthea Limited (ASX:OPT) is advancing its proprietary VEGF-C/D 'trap' inhibitor, sozinibercept, to address the high unmet need for improved visual outcomes in patients with wet age-related macular degeneration (AMD). The company anticipates topline data for its pivotal COAST and ShORe trials in early and mid-CY2025, with the current cash expected to fund operations into 3Q CY2025.

Executive commentary on sozinibercept's potential

Sozinibercept, a first-in-class VEGF-C/D 'trap' inhibitor, has the potential to improve vision for millions of patients with wet AMD. The upcoming topline data from the COAST and ShORe trials in early and mid-CY2025 will provide crucial insights into the efficacy and safety profile of sozinibercept. We are dedicated to advancing this innovative therapy to transform patient outcomes and address the limitations of current anti-VEGF-A therapies.

Outlook for Opthea and sozinibercept

Opthea (ASX:OPT) is positioned to revolutionize the treatment of wet AMD with its lead asset, sozinibercept, which has demonstrated superiority in combination with standard of care anti-VEGF-A therapies. The company anticipates substantial market opportunity and aims to provide a differentiated combination approach targeting better visual outcomes. With the potential to disrupt the treatment paradigm and a dedicated leadership team, Opthea is focused on advancing sozinibercept to address the high unmet need in the wet AMD market. The upcoming topline data from the COAST and ShORe trials will be pivotal in shaping the future of sozinibercept and its potential to transform patient outcomes.